The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Aclaris Theraputics Inc (ACRS) COM 00461U105 660 634,455 SH   SOLE   634,455 0 0
Aeglea Biotherapeutics Inc (AGLE) COM 00773J103 6,017 1,291,151 SH   SOLE   1,291,151 0 0
Arcus Biosciences, Inc. (RCUS) COM 03969F109 4,627 333,333 SH   SOLE   333,333 0 0
Atreca (BCEL) CL A COM 04965G109 6,416 387,653 SH   SOLE   387,653 0 0
AVROBIO, Inc. (AVRO) COM 05455M100 15,712 1,009,779 SH   SOLE   1,009,779 0 0
BridgeBio (BBIO) COM 10806X102 115,693 3,989,412 SH   SOLE   3,989,412 0 0
Eidos Therapeutics, Inc. (EIDIX) COM 28249H104 55,047 1,123,630 SH   SOLE   1,123,630 0 0
Marker Therapeutics, Inc. (MRKR) COM 57055L107 3,800 2,000,000 SH   SOLE   2,000,000 0 0
Nabriva Therapeutics plc (NBRV) SHS G63637105 1,098 1,910,287 SH   SOLE   1,910,287 0 0
ObsEva SA (OBSV) COM H5861P103 3,341 1,386,338 SH   SOLE   1,386,338 0 0
Sunesis Pharmaceuticals, Inc. (SNSS) COM 867328700 4,190 10,100,000 SH   SOLE   10,100,000 0 0
Syndax Pharmaceuticals Inc. (SNDX) COM 87164F105 9,599 875,000 SH   SOLE   875,000 0 0
Verona Pharma plc (VRNA) COM 925050106 1,828 443,596 SH   SOLE   443,596 0 0
Zosano Pharma Corporation (ZSAN) COM 98979H202 1,528 2,718,226 SH   SOLE   2,718,226 0 0